First all-female tavi trial shows excellent outcomes for women receiving edwards valves

London--(business wire)--edwards lifesciences (nyse: ew) today announced the results from the rheia trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (tavi). presenting one-year results during a hot line session at the esc congress 2024, investigators reported superior outcomes for women receiving the edwards sapien 3 ultra or sapien 3 ultra resilia valves as compared to those receiving surgical aortic valve replacement.
EW Ratings Summary
EW Quant Ranking